Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2024 - 2032

Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2024 - 2032



The global multiple sclerosis market size is expected to reach USD 33.57 billion by 2032, according to a new study by Polaris Market Research. The report “Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increased emphasis on research and development (R&D) for the creation of ground-breaking pharmaceuticals by prominent industry participants is credited with the global market's expansion. For instance, Adamas Pharmaceuticals Inc. announced findings from a phase 3 clinical trial evaluating ADS-5102, an investigational amantadine agent designed to treat patients with multiple sclerosis (MS), in December 2020.

Product introductions, escalating governmental efforts to improve treatment and care accessibility, and the rising incidence of multiple sclerosis are anticipated to drive market growth.

The growing global impact of multiple sclerosis is causing increasing concern among healthcare providers and governments. The disease's rising prevalence has compelled governments in a number of countries to take proactive measures, such as developing guidelines and recommendations.

Also, government organizations are launching a variety of awareness campaigns to educate patients about the various treatment options which are available.

For instance, the German Multiple Sclerosis Society runs three to four industries in Germany to help people with Multiple Sclerosis. They organize a World MS Day competition every May 31st with the goal of removing accessibility barriers and extending the support network for those affected by multiple sclerosis.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/global-multiple-sclerosis-market/request-for-sample

Monoclonal antibodies are becoming more popular in the treatment of multiple sclerosis. Many companies are committed to developing new drugs for multiple sclerosis by leveraging the potential of these antibodies. Furthermore, global demand for humanized monoclonal antibodies, a common class of immunosuppressive drugs used to treat multiple sclerosis, is increasing. Particularly, Ocrevus, introduced by F. Hoffmann-La Roche Ltd., has emerged as the biggest drug, contributing to a substantial revenue and contributing to the market's continuous growth.

Multiple Sclerosis Market Report Highlights

The immunomodulators segment held the largest revenue share in the multiple sclerosis market. The expansion of immunomodulator treatment options and the introduction of new products for treating the disease is contribute to the growth of the market.

The oral segment is witnessed for the fastest market growth during the forecast period. owing to the launch of new products and the incline towards the oral drugs are the key factors which bolster the growth of the segment.

North America accounted for the largest market share. The north america is the most important market for companies such as Biogen, Novartis AG, and Sanofi SA. As a result, these companies are prioritizing the introduction of their most recent pharmaceuticals in market.

The Asia-Pacific region witnessed for the fastest growth in the multiple sclerosis market, the substantial growth rate is ascribed to the enhanced distribution networks of an pharmaceutical companies in the region. The growing implementation of government initiatives in a number of countries aimed at lowering the costs associated with MS treatment is a key driver driving the region's demand for MS drugs.

The global key market players include Hoffmann-La Roche Ltd., Bayer Healthcare AG, Teva Pharmaceuticals, GlaxoSmithKline, AbbVie, Inc., Sonafi Pasteur, Pfizer Inc., Merck & Company, Novartis AG, AB Science, and Opexa.

Polaris Market Research has segmented the multiple sclerosis market report based on drug type, route of administration and region:

Multiple Sclerosis, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

Immunosuppressants
  • Lemtarda
  • Ocrelizumab
  • Zinbryta
  • Aubagio
Immunomodulators
  • Ampyra
  • Capxone
  • Betaseron/Extavia
  • Gilneya
  • Avonex/Plegridy
  • Tyasabri
  • Rebif
  • Teucifidera
Multiple Sclerosis, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Injectable Agents

Oral Agents

Multiple Sclerosis, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America
  • U.S.
  • Canada
Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
Latin America
  • Argentina
  • Brazil
  • Mexico
Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Multiple Sclerosis Market Insights
4.1. Multiple Sclerosis Market – Industry Snapshot
4.2. Multiple Sclerosis Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rise in the number of FDA approval will drive the growth of the market
4.2.1.2. Surge in the investment for healthcare infrastructure will bolster the growth of the market
4.2.2. Restraints and Challenges
4.2.2.1. High cost associated with the drugs hindering the growth of the market
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Multiple Sclerosis Industry trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Multiple Sclerosis Market, by Drug type
5.1. Key Findings
5.2. Introduction
5.2.1. Global Multiple Sclerosis, by Drug type, 2019-2032 (USD Billion)
5.3. Immunosuppressants
5.3.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
5.3.2. Lemtarda
5.3.2.1. Global Multiple Sclerosis Market, by Lemtarda, by Region, 2019-2032 (USD Billion)
5.3.3. Ocrelizumab
5.3.3.1. Global Multiple Sclerosis Market, by Ocrelizumab, by Region, 2019-2032 (USD Billion)
5.3.4. Zinbryta
5.3.4.1. Global Multiple Sclerosis Market, by Zinbryta, by Region, 2019-2032 (USD Billion)
5.3.5. Aubagio
5.3.5.1. Global Multiple Sclerosis Market, by Aubagio, by Region, 2019-2032 (USD Billion)
5.4. Immunosuppressants
5.4.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
5.4.2 Ampyra
5.4.21. Global Multiple Sclerosis Market, by Ampyra, by Region, 2019-2032 (USD Billion)
5.4.3 Capxone
5.4.3.1. Global Multiple Sclerosis Market, by Capxone, by Region, 2019-2032 (USD Billion)
5.4.4 Betaseron/Extavia
5.4.4.1. Global Multiple Sclerosis Market, by Betaseron/Extavia, by Region, 2019-2032 (USD Billion)
5.4.5 Gilneya
5.4.5.1. Global Multiple Sclerosis Market, by Gilneya, by Region, 2019-2032 (USD Billion)
5.4.6 Avonex/Plegridy
5.4.6.1. Global Multiple Sclerosis Market, by Avonex/Plegridy, by Region, 2019-2032 (USD Billion)
5.4.7 Tyasabri
5.4.7.1. Global Multiple Sclerosis Market, by Tyasabri, by Region, 2019-2032 (USD Billion)
5.4.8 Rebif
5.4.8.1. Global Multiple Sclerosis Market, by Rebif, by Region, 2019-2032 (USD Billion)
5.4.9 Teucifidera
5.4.91. Global Multiple Sclerosis Market, by Teucifidera, by Region, 2019-2032 (USD Billion)
6. Global Multiple Sclerosis Market, by Route of Administration
6.1. Key Findings
6.2. Introduction
6.2.1. Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
6.3. Injectable Agents
6.3.1. Global Multiple Sclerosis Market, by Injectable Agents, by Region, 2019-2032 (USD Billion)
6.4. Oral Agents
6.4.1. Global Multiple Sclerosis Market, by Oral Agents, by Region, 2019-2032 (USD Billion)
7. Global Multiple Sclerosis Market, by Geography
7.1. Key findings
7.2. Introduction
7.2.1. Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
7.3. Multiple Sclerosis Market – North America
7.3.1. North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.3.2. North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.3.3. Multiple Sclerosis Market – U.S.
7.3.3.1. U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.3.3.2. U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.3.4. Multiple Sclerosis Market – Canada
7.3.4.1. Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.3.4.2. Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4. Multiple Sclerosis Market – Europe
7.4.1. Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.2. Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.3. Multiple Sclerosis Market – UK
7.4.3.1. UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.3.2. UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.4. Multiple Sclerosis Market – France
7.4.4.1. France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.4.2. France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.5. Multiple Sclerosis Market – Germany
7.4.5.1. Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.5.2. Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.6. Multiple Sclerosis Market – Italy
7.4.6.1. Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.6.2. Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.7. Multiple Sclerosis Market – Spain
7.4.7.1. Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.7.2. Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.8. Multiple Sclerosis Market – Netherlands
7.4.8.1. Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.8.2. Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.4.9. Multiple Sclerosis Market – Russia
7.4.9.1. Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.4.9.2. Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5. Multiple Sclerosis Market – Asia Pacific
7.5.1. Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.2. Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5.3. Multiple Sclerosis Market – China
7.5.3.1. China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.3.2. China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5.4. Multiple Sclerosis Market – India
7.5.4.1. India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.4.2. India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5.5. Multiple Sclerosis Market – Malaysia
7.5.5.1. Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.5.2. Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5.6. Multiple Sclerosis Market – Japan
7.5.6.1. Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.6.2. Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5.7. Multiple Sclerosis Market – Indonesia
7.5.7.1. Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.7.2. Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.5.8. Multiple Sclerosis Market – South Korea
7.5.8.1. South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.5.8.2. South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.6. Multiple Sclerosis Market – Middle East & Africa
7.6.1. Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.6.2. Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.6.3. Multiple Sclerosis Market – Saudi Arabia
7.6.3.1. Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.6.3.2. Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.6.4. Multiple Sclerosis Market – UAE
7.6.4.1. UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.6.4.2. UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.6.5. Multiple Sclerosis Market – Israel
7.6.5.1. Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.6.5.2. Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.6.6. Multiple Sclerosis Market – South Africa
7.6.6.1. South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.6.6.2. South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.7. Multiple Sclerosis Market – Latin America
7.7.1. Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.7.2. Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.7.3. Multiple Sclerosis Market – Mexico
7.7.3.1. Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.7.3.2. Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.7.4. Multiple Sclerosis Market – Brazil
7.7.4.1. Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.7.4.2. Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
7.7.5. Multiple Sclerosis Market – Argentina
7.7.5.1. Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
7.7.5.2. Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
8. Competitive Landscape
8.1. Expansion and Acquisition Analysis
8.1.1. Expansion
8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
9.1. Hoffmann-La Roche Ltd.
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Recent Development
9.2. Bayer Healthcare AG
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Recent Development
9.3. Teva Pharmaceuticals
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Recent Development
9.4. GlaxoSmithKline
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Recent Development
9.5. AbbVie Inc.
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Recent Development
9.6. Sonafi Pasteur
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Recent Development
9.7. Pfizer Inc
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Recent Development
9.8. Merck & Company
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Recent Development
9.9. Novartis AG
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Recent Development
9.10. AB Science
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Recent Development
9.11. Opexa
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings